AUX 101

Drug Profile

AUX 101

Latest Information Update: 26 Mar 2007

Price : $50

At a glance

  • Originator Auxeris Therapeutics (CEASED)
  • Class Osteoporosis therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fracture; Osteoporosis

Most Recent Events

  • 27 Aug 2003 Preclinical trials in Spinal fusion in USA (unspecified route)
  • 27 Aug 2003 Preclinical trials in Fracture in USA (unspecified route)
  • 27 Aug 2003 Preclinical trials in Osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top